Taken together, these observations suggest that the combined histological analyses of the expression levels of EGFR, pAkt, NF-κB p65 and/or MIC-1 with the current molecular biomarkers used clinically may constitute a promising strategy to optimize the efficacy of diagnosis, prediction of prognosis, long-term follow-up and choice of therapeutic treatment of PC patients. The gene discussed is NFKB1; the disease is pachyonychia congenita.